Phase I : Cediranib in Combination With Lomustine Chemotherapy in Recurrent Malignant Brain Tumour

A Phase I, Open Label, Multi-Centre Study to Assess the Safety and Tolerability of Cediranib (RECENTIN™, AZD2171) in Combination With Lomustine Chemotherapy for Patients With Primary Recurrent Malignant Brain Tumours for Whom Lomustine Would be a Standard Therapy

This is a Phase I, open-label, multi-centre study designed to assess the safety and tolerability of Cediranib in combination with lomustine in patients with primary recurrent malignant brain tumour.

Inclusion Criteria:

• Primary recurrent malignant brain tumour for whom lomustine would be standard therapy - diagnosis & stage
• Patients received no more than 2 previous systemic chemotherapy regimes
• Life Expectancy > 12 weeks
• Patients must be at least 3 months from the completion of cranial radiation therapy

Exclusion Criteria:

• History of poorly controlled high blood pressure
• Recent major surgery prior to entry into the study